Blood Cancers

Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease across leukemia subtypes.

Years after losing my brother to Hodgkin’s lymphoma, I learned something about how he felt facing a terminal diagnosis by studying an old Polaroid.

It’s easy to think of scientific researchers as existing in a vacuum.

Nutrition is a challenge for many patients with cancer.

Cancer is one of the most expensive medical conditions to treat in the U.S.

JAK inhibitor treatment is associated with a reduction in risk of thromboembolic events for patients with myeloproliferative neoplasms.

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Treatment with the CAR T-cell therapy cema-cel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphoma.

The FDA has granted orphan drug designation to the oral agent OPN-6602 for the treatment of patients with relapsed or refractory multiple myeloma.

As we observe World Cancer Day, I’m reflecting on my own family’s experience with blood cancer.

Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission following second-line salvage therapy.

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the challenges of deafness.

From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple myeloma and other blood cancers.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

Researchers have found an increased frequency of severe maternal morbidity and obstetric complications among women who received a diagnosis of a hematological malignancy during pregnancy.

The risk of cardiovascular disease is elevated in cancer survivors, regardless of treatment, and is influenced by cancer type and treatment-related factors.

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my own pace.

Although Jakafi has been approved for patients with higher-risk myelofibrosis, those with lower-risk disease may also benefit from this treatment.

An expert explained the burden that red blood cell transfusions can place on patients with MDS.

Having myelodysplastic syndromes has taught me to cherish every day and to pursue the things that matter to me, like publishing a book I’ve been writing.

The Shorespan-007 trial will investigate the new drug among patients with essential thrombocythemia who have not previously received cytoreductive therapy.

Bispecific antibodies connect the immune system with cancer cells. They offer an efficacious treatment option, but there are side effects.

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.

Just like athletes in the Olympics, it's important for cancer survivors to keep track of everything they feel and to know their bodies well.

The National Comprehensive Cancer Network now recommends Rytelo for patients with myelodysplastic syndrome who require blood transfusions.

Eighty percent of patients with relapsed or refractory Waldenstrom’s macroglobulinemia responded to treatment with iopofosine I 131, researchers found.

Researchers identified five traits that may increase a person’s chance of experiencing polycythemia vera progression.